Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096822 | 1.00 | SLC6A9 (1.00) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL30510966 | 1.00 | SLC6A9 (1.00) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL1105709 | 0.95 | SLC6A9 (0.91) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL3871633 | 0.95 | SLC6A9 (0.91) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL1105671 | 0.94 | SLC6A9 (0.89) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL1096140 | 0.93 | SLC6A9 (0.86) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL1105660 | 0.91 | SLC6A9 (1.00) | SLC6A9SLC6A5 | |
| SCHEMBL1096536 | 0.91 | SLC6A9 (1.00) | SLC6A9SLC6A5 | |
| SCHEMBL1460872 | 0.90 | SLC6A9 (0.82) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL1123456 | 0.90 | SLC6A9 (0.82) | SLC6A9SLC6A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153679-B2 | Radiolabelled inhibitors of the glycine 1 transporter | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100111862-A1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111862-A1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | SLC1A5, SLC7A1, SLC1A1 | SLC6A9 14/4885SLC6A5 7/4885KCNH2 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.